Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.